Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Sirion Biotech.

    Client Virtual Booth

    SIRION BIOTECH

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Sirion Biotech
    Germany Flag
    Country
    Country
    Germany
    Address
    Address
    Am Klopferspitz 19 82152 Martinsried
    Telephone
    Telephone
    +49 89 700 961 99 9
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.sirion-biotech.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    PerkinElmer’s SIRION Biotech Teams with Centre for Genomic Regulation to Develop New Generation AAV Vectors for Type 1 and Type 2 Diabetes Gene Therap...

    Details:

    The collaboration combines SIRION’s adeno-associated virus (AAV) vectors for type 1 and type 2 diabetes gene therapy and expertise in viral vector development and production with CRG’s deep knowledge of genetic regulatory mechanisms.


    Lead Product(s): AAV-based Gene Therapy

    Therapeutic Area: Endocrinology Product Name: Undisclosed

    Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: PerkinElmer

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration February 16, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    SIRION Biotech Announces Collaboration with Sanofi to Innovate Gene Therapy Treatments with Improved Adeno-Associated Virus Capsids

    Details:

    Sanofi, together with SIRION will develop new and modified AAV capsids that exhibit a safe product profile with improved specificity and higher gene delivery efficiency.


    Lead Product(s): AAV capsid-gene therapy

    Therapeutic Area: Genetic Disease Product Name: Undisclosed

    Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Sanofi

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration February 23, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    SIRION Biotech GmbH Licensed Its LentiBOOST™ Transduction Technology to Cellectis

    Details:

    Through this license agreement, SIRION Biotech GmbH (“SIRION”) granted Cellectis non-exclusive right under its proprietary lentiviral transduction enhancer LentiBOOST™.


    Lead Product(s): Allogeneic CAR T-cells

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Cellectis

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement January 07, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Mustang Bio Licenses LentiBOOST™ Technology from SIRION Biotech

    Details:

    Mustang has acquired rights to SIRION’s LentiBOOST™ technology for the development of MB-207, Mustang’s lentiviral gene therapy for the treatment of patients with X-linked severe combined immunodeficiency.


    Lead Product(s): MB-207

    Therapeutic Area: Genetic Disease Product Name: MB-207

    Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Mustang Bio

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement October 06, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search